Kiyong Song is a corporate healthcare and life sciences partner in the New York office of Kirkland & Ellis LLP, advising private equity sponsors, strategic acquirers, and growth-stage companies on complex, high-value transactions at the intersection of healthcare, life sciences and technology. He serves as lead regulatory counsel on mergers and acquisitions, carve-outs, joint ventures and strategic investments, guiding regulatory diligence, structuring, risk allocation and post-closing integration for pharmaceutical and biotech companies, medical device manufacturers, CDMOs, CROs, laboratories, API suppliers, specialty pharmacies, advanced therapeutics developers, digital health platforms and data-driven healthcare businesses.
His practice spans the full product life cycle — from clinical development and FDA strategy through commercialization, inspections, recalls and enforcement — with particular strength in innovative therapeutics, medical devices, AI-enabled technologies and regulated data platforms. He regularly advises on HIPAA, emerging consumer health data laws, AI/ML governance, the 21st Century Cures Act, and federal and state fraud and abuse frameworks, translating complex regulatory risk into pragmatic transaction strategy and enterprise value protection.
